Anbio Biotechnology shares surge 10.02% premarket driven by tech innovation and rising global diagnostics demand.

Anbio Biotechnology surged 10.02% in premarket trading, driven by a bullish article highlighting its 142% year-to-date gains and $2.01 billion market capitalization. The piece emphasized the company’s diversified diagnostic technology platforms (FIA, PCR, ChLIA, LAMP, LFIA), global expansion, and post-pandemic pivot to non-COVID diagnostics. These factors underscored investor confidence in Anbio’s scalable business model and long-term growth potential in the $160 billion diagnostics sector. The article also noted institutional accumulation on dips and strong margins, aligning with the stock’s upward momentum amid heightened retail and institutional interest.